Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A motive for killing: effector functions of regulated lytic cell death.

Bliss-Moreau M, Chen AA, D'Cruz AA, Croker BA.

Immunol Cell Biol. 2017 Feb;95(2):146-151. doi: 10.1038/icb.2016.113. Epub 2016 Nov 9. Review.

2.

Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.

Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC.

Oncotarget. 2015 Apr 10;6(10):8062-70.

3.

Identification of p38β as a therapeutic target for the treatment of Sézary syndrome.

Bliss-Moreau M, Coarfa C, Gunaratne PH, Guitart J, Krett NL, Rosen ST.

J Invest Dermatol. 2015 Feb;135(2):599-608. doi: 10.1038/jid.2014.367. Epub 2014 Aug 22.

4.

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD.

Cell. 2012 Aug 3;150(3):575-89. doi: 10.1016/j.cell.2012.06.032.

5.

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD.

J Clin Invest. 2012 Mar;122(3):948-62. doi: 10.1172/JCI60455. Epub 2012 Feb 22.

Supplemental Content

Loading ...
Support Center